Federal Register / Vol. 85, No. 248 / Monday, December 28, 2020 / Notices 84359 

Council; Diabetes, Endocrinology and 

Metabolic Diseases Subcommittee. 

Date: May 12–13, 2021. 

Open: May 13, 2021, 10:00 a.m. to 11:30 

a.m. 

Agenda: To review the Division’s scientific 

and planning activities. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Virtual 

Meeting). 

Closed: May 13, 2021, 11:45 a.m. to 1:15 

p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Virtual 

Meeting). 

Contact Person: Karl F. Malik, Ph.D., 

Director Division of Extramural Activities, 

National Institutes of Diabetes and Digestive 

and Kidney Diseases, 6707 Democracy 

Boulevard, Room 7329, MSC 5452, Bethesda, 

MD 20892 (301) 594–4757, malikk@

niddk.nih.gov. 

Name of Committee: National Diabetes and 

Digestive and Kidney Diseases Advisory 

Council; Digestive Diseases and Nutrition 

Subcommittee. 

Date: May 12–13, 2021. 

Open: May 13, 2021, 10:00 a.m. to 11:30 

a.m. 

Agenda: To review the Division’s scientific 

and planning activities. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Virtual 

Meeting). 

Closed: May 13, 2021, 11:45 a.m. to 1:15 

p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Virtual 

Meeting). 

Contact Person: Karl F. Malik, Ph.D., 

Director Division of Extramural Activities, 

National Institutes of Diabetes and Digestive 

and Kidney Diseases, 6707 Democracy 

Boulevard, Room 7329, MSC 5452 Bethesda, 

MD 20892, (301) 594–4757 malikk@

niddk.nih.gov. 

Name of Committee: National Diabetes and 

Digestive and Kidney Diseases Advisory 

Council; Kidney, Urologic and Hematologic 

Diseases Subcommittee. 

Date: May 12–13, 2021. 

Open: May 13, 2021, 10:00 a.m. to 11:30 

a.m. 

Agenda: To review the Division’s scientific 

and planning activities. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Virtual 

Meeting). 

Closed: May 13, 2021, 11:45 a.m. to 1:15 

p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Virtual 

Meeting). 

Contact Person: Karl F. Malik, Ph.D., 

Director Division of Extramural Activities, 

National Institutes of Diabetes and Digestive 

and Kidney Diseases, 6707 Democracy 

Boulevard, Room 7329, MSC 5452, Bethesda, 

MD 20892, (301) 594–4757, malikk@

niddk.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: 

www.niddk.nih.gov/fund/divisions/DEA/ 

Council/coundesc.htm., where an agenda and 

any additional information for the meeting 

will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: December 18, 2020. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2020–28524 Filed 12–23–20; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: Use of A CD47 

Phosphorodiamidate Morpholino 

Oligomer for the Treatment, 

Prevention, and Diagnosis Of Cancer 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Cancer Institute, 

an institute of the National Institutes of 

Health, Department of Health and 

Human Services, is contemplating the 

grant of an Exclusive Patent License to 

practice the inventions embodied in the 

Patents and Patent Applications listed 

in the Supplementary Information 

section of this notice to Morphiex 

Biotherapeutics (‘‘Morphiex’’) located in 

Boston, MA. 

DATES: Only written comments and/or 

applications for a license which are 

received by the National Cancer 

Institute’s Technology Transfer Center 

on or before January 12, 2021 will be 

considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, and 

comments relating to the contemplated 

an Exclusive Patent License should be 

directed to: Jaime M. Greene, Senior 

Licensing and Patenting Manager at 

greenejaime@mail.nih.gov. 

SUPPLEMENTARY INFORMATION: 

Intellectual Property 

• U.S. Provisional Patent Application 

No. 60/850,132, filed October 6, 2006, 

now abandoned (HHS Ref. No. E–227– 

2006–0–US–01); 

• U.S. Provisional Patent Application 

No. 60/864,153, filed November 02, 

2006, now abandoned (HHS Ref. No. E– 

227–2006–1–US–01); 

• U.S. Provisional Patent Application 

No. 60/888,754, filed February 07, 2007, 

now 

• abandoned (HHS Ref. No. E–227– 

2006–2–US–01); 

• U.S. Provisional Patent Application 

No. 60/910,549, filed April 06, 2007, 

now abandoned (HHS Ref. No. E–227– 

2006–3–US–01); 

• U.S. Provisional Patent Application 

No. 60/956,375, filed August 16, 2007, 

now abandoned (HHS Ref. No. E–227– 

2006–4–US–01); 

• PCT Patent Application No. PCT/ 

2007/080647, filed October 5, 2007, now 

abandoned (HHS Ref. No. E–227–2006– 

5–PCT–01); 

• U.S. Patent No. 8,236,313, filed 

April 3, 2009, issued August 7, 2012 

(HHS Ref. No. E–227–2006–5–US–02); 

• Canadian Patent Application No. 

2,665,287, October 5, 2007 (HHS Ref. 

No. E–227–2006–5–CA–03); 

• Australian Patent No. 2007319576, 

filed October 5, 2007, issued May 1, 

2014 (HHS Ref. No. E–227–2006–5–AU– 

04); 

• European Patent No. 2076537, filed 

March 27, 2009, issued August 22, 2018 

(HHS Ref. No. E–227–2006–5–EP–05); 

• U.S. Patent Application No. 13/ 

546,931, filed July 11, 2012 (HHS Ref. 

No. E–227–2006–5–US–06); 

• U.S. Patent Number 8,557,788, filed 

July 11, 2012, issued October 15, 2013 

(HHS Ref. No. E–227–2006–5–US–07); 

• European Patent No. 2695896, filed 

October 5, 2007, issued August 22, 

2018(HHS Ref. No. E–227–2006–5–EP– 

08); 

• Australian Patent No. 2014201936, 

filed April 4, 2014, issued October 20, 

2016 (HHS Ref. No. E–227–2006–5–AU– 

09); 

• U.S. Patent No. 10370439, filed 

September 29, 2014, issued August 6, 

2019 (HHS Ref. No. E–227–2006–5–US– 

10); 

• Australian Patent No. 2016238894, 

filed October 6, 2016, issued February 

22, 2018 (HHS Ref. No. E–227–2006–5– 

AU–11); 

• Australian Patent No. 2018200921, 

filed February 8, 2018, issued 

September 24, 2020 (HHS Ref. No. E– 

227–2006–5–AU–12) 


tkelley on DSKBCP9HB2PROD with NOTICES
84360 Federal Register / Vol. 85, No. 248 / Monday, December 28, 2020 / Notices 

• European Patent Application No. 

18183780.8, filed July 16, 2018 (HHS 

Ref. No. E–227–2006–5–EP–13); 

• German Patent No. 2076537, issued 

August 22, 2018, filed March 27, 2009 

(HHS Ref. No. E–227–2006–5–DE–14); 

• French Patent No. 2076537, issued 

August 22, 2018, filed March 27, 2009 

(HHS Ref. No. E–227–2006–5–FR–15); 

• United Kingdom Patent No. 

2076537, issued August 22, 2018, filed 

March 27, 2009 (HHS Ref. No. E–227– 

2006–5–GB–16); 

• German Patent No. 2695896, issued 

August 22, 2018, filed October 5, 2007 

(HHS Ref. No. E–227–2006–5–DE–17); 

• French Patent No. 2695896, issued 

August 22, 2018, filed October 5, 2007 

(HHS Ref. No. E–227–2006–5–FR–18); 

• United Kingdom Patent No. 

2695896, issued August 22, 2018, filed 

October 5, 2007 (HHS Ref. No. E–227– 

2006–5–GB–19); 

• U.S. Patent Application No. 16/ 

443,415, filed June 17, 2019 (HHS Ref. 

No. E–227–2006–5–US–20); 

• Australia Patent Application No. 

2020230283, filed September 10, 2020 

Pending (HHS Ref. No. E–227–2006–5– 

AU–21); 

• Provisional Patent Application No. 

61/621,994, filed April 9, 2012, now 

abandoned (HHS Ref. No. E–086–2012– 

0–US–01); 

• Provisional Patent Application No. 

61/735,701, filed December 11, 2012, 

now abandoned (HHS Ref. No. E–086– 

2012–1–US–01); 

• PCT Patent Application No. PCT/ 

US2013/035838, filed April 9, 2013, 

now abandoned (HHS Ref. No. E–086– 

2012–2–PCT–01); 

• Australian Patent No. 2013246040, 

issued March 14, 2019, filed April 9, 

2013 (HHS Ref. No. E–086–2012–2–AU– 

02); 

• Canadian Patent No. 2869913, 

issued September 10, 2019, filed April 

9, 2013 (HHS Ref. No. E–086–2012–2– 

CA–03);Start Printed Page 327 

• European Patent No. 2836591, filed 

April 9, 2013, issued June 6, 2018 (HHS 

Ref. No. E–086–2012–2–EP–04); 

• US Patent No. 10407665, issued 

September 10, 2019, filed October 2, 

2014 (HHS Ref. No. E–086–2012–2–US– 

05); 

• German Patent No. 2836591, issued 

June 6, 2018, filed April 9, 2013 (HHS 

Ref. No. E–086–2012–2–DE–07); 

• French Patent No. 2836591, issued 

June 6, 2018, filed April 9, 2013 (HHS 

Ref. No. E–086–2012–2–FR–08); 

• United Kingdom Patent No. 

2836591, issued June 6, 2018, filed 

April 9, 2013 (HHS Ref. No. E–086– 

2012–2–GB–09); 

• US Patent Application No. 16/ 

521,251, filed July 24, 2019 (HHS Ref. 

No. E–086–2012–2–US–10); 

• Provisional Patent Application No. 

61/086,991, filed August 7, 2008, now 

abandoned (HHS Ref. No. E–153–2008– 

0–US–01); 

• PCT Patent Application No. PCT/ 

US2009/052902, filed August 5, 2009, 

now abandoned (HHS Ref. No. E–153– 

2008–0–PCT–02); 

• Australian Patent No. 2009279676, 

issued July 30, 2015, filed August 5, 

2009 (HHS Ref. No. E–153–2008–0–AU– 

03); 

• Canadian Patent No. 2732102, 

issued January 2, 2018, filed August 5, 

2009 (HHS Ref. No. E–153–2008–0–CA– 

04); 

• European Patent No. 2340034, filed 

August 5, 2009, issued January 27, 2016 

(HHS Ref. No. E–153–2008–0–EP–05); 

• US Patent No. 8951527, issued 

February 10, 2015, filed February 3, 

2011 (HHS Ref. No. E–153–2008–0–US– 

06); 

• German Patent No. 

602009036069.8, issued January 27, 

2016, filed August 5, 2009 (HHS Ref. 

No. E–153–2008–0–DE–07); 

• French Patent No. 2340034, issued 

January 27, 2016, filed August 5, 2009 

(HHS Ref. No. E–153–2008–0–FR–08); 

• United Kingdom Patent No. 

2340034, issued January 27, 2016, filed 

August 5, 2009 (HHS Ref. No. E–153– 

2008–0–GB–09); 

• Provisional Patent Application No. 

61/779,587, filed March 13, 2013, now 

abandoned (HHS Ref. No. E–296–2011– 

0–US–01); 

• PCT Patent Application No. PCT/ 

US2014/025989, filed March 13, 2014, 

now abandoned (HHS Ref. No. E–296– 

2011–0–PCT–02); 

• Australian Patent No. 2014244083, 

issued January 10, 2019, filed March 13, 

2014, now abandoned (HHS Ref. No. E– 

296–2011–0–AU–03); 

• Canadian Patent Application No. 

2905418, filed March 13, 2014 (HHS 

Ref. No. E–296–2011–0–CA–04); 

• European Patent Application No. 

14718255.4, filed March 13, 2014 (HHS 

Ref. No. E–296–2011–0–EP–05); 

• US Patent Application No. 14/ 

775,428, filed September 11, 2015 (HHS 

Ref. No. E–296–2011–0–US–06). 

• U.S. Provisional Patent Application 

No. 62/062,675, filed October 10, 2014, 

now abandoned (HHS Ref. No E–263– 

2014–0–US–01); 

• PCT Patent Application No. PCT/ 

US2015/055029, filed October 9, 2015, 

now abandoned (HHS Ref. No E–263– 

2014–0–PCT–02); 

• Australia Patent Application No. 

2015329696, filed October 9, 2015(HHS 

Ref. No E–263–2014–0–AU–03); 

• Canadian Patent Application No. 

2964173, filed October 9, 2015 (HHS 

Ref. No. E–263–2014–0–CA–04); 

• European Patent No. 3204420, filed 

October 9, 2015, issued September 2, 

2020 (HHS Ref. No E–263–2014–0–EP– 

05); 

• U.S. Patent Application No. 15/ 

517,345, filed April 6, 2017 (HHS Ref. 

No E–263–2014–0–US–06); 

• German Patent No. 3204420, issued 

September 2, 2020, filed October 9, 2015 

(HHS Ref. No E–263–2014–0–DE–07); 

• French Patent No. 3204420, issued 

September 2, 2020, filed October 9, 2015 

(HHS Ref. No E–263–2014–0–FR–08); 

• United Kingdom Patent No. 

3204420, issued September 2, 2020, 

filed October 9, 2015 (HHS Ref. No E– 

263–2014–0–GB–09). 

The patent rights in these inventions 

have been assigned and/or exclusively 

licensed to the government of the 

United States of America. 

The prospective exclusive license 

territory may be worldwide and the 

field of use may be limited to the use 

of all of the above Licensed Patent 

Rights for the following: ‘‘The use of the 

CD47 phosphorodiamidate morpholino 

oligomers (PMO, morpholino, Sequence: 

5’- 

CGTCACAGGCAGGACCCACTGCCCA3’), in combination with radiotherapy, 

for the treatment, prevention, and 

diagnosis of cancer.’’ For the Licensed 

Patent Rights encompassed by 

technologies with the HHS. Ref. No. 

starting with E–263–2014, the 

prospective exclusive license territory 

may be worldwide and the field of use 

may be limited to: ‘‘The use of the CD47 

phosphorodiamidate morpholino 

oligomers (PMO, morpholino, Sequence: 

5’- 

CGTCACAGGCAGGACCCACTGCCCA3’) for the treatment, prevention, and 

diagnosis of cancer.’’ 

This technology concerns CD47, 

originally named integrin-associated 

protein, which is a receptor for 

thrombospondin-1 (TSP1), a major 

component of platelet a-granules from 

which it is secreted on platelet 

activation. A number of important roles 

for CD47 have been defined in 

regulating the migration, proliferation, 

and survival of vascular cells, and in 

regulation of innate and adaptive 

immunity. Nitric Oxide (NO) plays an 

important role as a major intrinsic 

vasodilator, and it increases blood flow 

to tissues and organs. Disruption of this 

process leads to peripheral vascular 

disease, ischemic heart disease, stroke, 

diabetes and many more significant 

diseases. The inventors have discovered 

that TSP1 blocks the beneficial effects of 

NO and prevents it from dilating blood 

vessels and increasing blood flow to 

organs and tissues. Additionally, they 

discovered that this regulation requires 


tkelley on DSKBCP9HB2PROD with NOTICES
Federal Register / Vol. 85, No. 248 / Monday, December 28, 2020 / Notices 84361 

TSP1 interaction with its cell receptor, 

CD47. These inventors have also found 

that blocking TSP1–CD47 interaction 

through the use of antisense morpholino 

oligonucleotides, peptides or antibodies 

have several therapeutic benefits 

including the treatment of cancer. 

This notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective exclusive license will 

be royalty bearing, and the prospective 

exclusive license may be granted unless 

within fifteen (15) days from the date of 

this published notice, the National 

Cancer Institute receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR part 404. 

In response to this Notice, the public 

may file comments or objections. 

Comments and objections, other than 

those in the form of a license 

application, will not be treated 

confidentially, and may be made 

publicly available. 

License applications submitted in 

response to this Notice will be 

presumed to contain business 

confidential information and any release 

of information in these license 

applications will be made only as 

required and upon a request under the 

Freedom of Information Act, 5 U.S.C. 

552. 

Dated: December 17, 2020. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2020–28570 Filed 12–23–20; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

[Docket ID FEMA–2020–0002] 

Final Flood Hazard Determinations 

AGENCY: Federal Emergency 

Management Agency, DHS. 

ACTION: Notice. 

SUMMARY: Flood hazard determinations, 

which may include additions or 

modifications of Base Flood Elevations 

(BFEs), base flood depths, Special Flood 

Hazard Area (SFHA) boundaries or zone 

designations, or regulatory floodways on 

the Flood Insurance Rate Maps (FIRMs) 

and where applicable, in the supporting 

Flood Insurance Study (FIS) reports 

have been made final for the 

communities listed in the table below. 

The FIRM and FIS report are the basis 

of the floodplain management measures 

that a community is required either to 

adopt or to show evidence of having in 

effect in order to qualify or remain 

qualified for participation in the Federal 

Emergency Management Agency’s 

(FEMA’s) National Flood Insurance 

Program (NFIP). In addition, the FIRM 

and FIS report are used by insurance 

agents and others to calculate 

appropriate flood insurance premium 

rates for buildings and the contents of 

those buildings. 

DATES: The date of April 21, 2021 has 

been established for the FIRM and, 

where applicable, the supporting FIS 

report showing the new or modified 

flood hazard information for each 

community. 

ADDRESSES: The FIRM, and if 

applicable, the FIS report containing the 

final flood hazard information for each 

community is available for inspection at 

the respective Community Map 

Repository address listed in the tables 

below and will be available online 

through the FEMA Map Service Center 

at https://msc.fema.gov by the date 

indicated above. 

FOR FURTHER INFORMATION CONTACT: Rick 

Sacbibit, Chief, Engineering Services 

Branch, Federal Insurance and 

Mitigation Administration, FEMA, 400 

C Street SW, Washington, DC 20472, 

(202) 646–7659, or (email) 

patrick.sacbibit@fema.dhs.gov; or visit 

the FEMA Mapping and Insurance 

eXchange (FMIX) online at https://

www.floodmaps.fema.gov/fhm/fmx_

main.html. 

SUPPLEMENTARY INFORMATION: The 

Federal Emergency Management Agency 

(FEMA) makes the final determinations 

listed below for the new or modified 

flood hazard information for each 

community listed. Notification of these 

changes has been published in 

newspapers of local circulation and 90 

days have elapsed since that 

publication. The Deputy Associate 

Administrator for Insurance and 

Mitigation has resolved any appeals 

resulting from this notification. 

This final notice is issued in 

accordance with section 110 of the 

Flood Disaster Protection Act of 1973, 

42 U.S.C. 4104, and 44 CFR part 67. 

FEMA has developed criteria for 

floodplain management in floodprone 

areas in accordance with 44 CFR part 

60. 

Interested lessees and owners of real 

property are encouraged to review the 

new or revised FIRM and FIS report 

available at the address cited below for 

each community or online through the 

FEMA Map Service Center at https://

msc.fema.gov. 

The flood hazard determinations are 

made final in the watersheds and/or 

communities listed in the table below. 

(Catalog of Federal Domestic Assistance No. 

97.022, ‘‘Flood Insurance.’’) 

Michael M. Grimm, 

Assistant Administrator for Risk 

Management, Department of Homeland 

Security, Federal Emergency Management 

Agency. 

Community Community map repository address 

Los Angeles County, California and Incorporated Areas 

Docket No.: FEMA–B–1716 

City of El Segundo ................................................................................... City Hall, 350 Main Street, El Segundo, CA 90245. 

City of Hermosa Beach ............................................................................ City Hall, 1315 Valley Drive, Hermosa Beach, CA 90254. 

City of Long Beach ................................................................................... City Hall, 333 West Ocean Boulevard, 9th Floor, Long Beach, CA 

90802. 

City of Los Angeles .................................................................................. Department of Public Works, 1149 South Broadway, Suite 810, Los 

Angeles, CA 90015. 

City of Malibu ............................................................................................ City Hall, 23825 Stuart Ranch Road, Malibu, CA 90265. 

City of Manhattan Beach .......................................................................... Engineering Department, 3621 Bell Avenue, Manhattan Beach, CA 

90266. 

City of Palos Verdes Estates ................................................................... City Hall, 340 Palos Verdes Drive West, Palos Verdes Estates, CA 

90274. 


tkelley on DSKBCP9HB2PROD with NOTICES